Clever Leaves and Biopharmaceutical Research Company to Partner for Landmark Cannabis Research Study in Collaboration with the University of California, Davis

by The initiative is part of Project Change Lives; Clever Leaves’ $25M product pledge to aid cannabis research in the U.S. The collaboration represents the Company’s first funded study with a research institution in the United States
July 27, 2021

NEW YORK, July 27, 2021 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for importing, analyzing and manufacturing controlled substances in the U.S., today announced a joint partnership with the intent to study the DNA sequence variation of three Clever Leaves’ cannabis cultivars as part of their Project Change Lives campaign. The University of California, Davis (“UC Davis”), through an accepted research sponsorship from BRC, will lead the extraction and analysis of DNA to elucidate genetic variants taken from various genetic lines of Cannabis sativa.